ArticleEuropean journal of medicinal chemistry2021
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.
Article in European journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Synthesis, Biological Evaluation and Structure-Activity Relationship of Juglone Derived Naphthoquinones as Potential Antipsoriatic Agents.Biomolecules · 2026Article
- A novel potent autophagy inhibitor HM-013 limits production of infectious dengue virus particles.Virology journal · 2025Article
- Design, Synthesis, and Biological Evaluation of 5,8-Dimethyl Shikonin Oximes as SARS-CoV-2 MMolecules (Basel, Switzerland) · 2025Article
- Exploiting the Anticancer, Antimicrobial and Antiviral Potential of Naphthoquinone Derivatives: Recent Advances and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
- PAV-05 Naphthoquinone Potently Inhibit Zika Virus Replication in Infected Cells.Current topics in medicinal chemistry · 2025Article
- Review
- Discovery of 5-Hydroxy-1,4-naphthoquinone (Juglone) Derivatives as Dual Effective Agents Targeting Platelet-Cancer Interplay through Protein Disulfide Isomerase Inhibition.Journal of medicinal chemistry · 2024Article
- Juglone, a plant-derived 1,4-naphthoquinone, binds to hydroxylamine oxidoreductase and inhibits the electron transfer to cytochromeApplied and environmental microbiology · 2023Article
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Shikonin and Juglone InhibitBiotech (Basel (Switzerland)) · 2023Article
- Review
- The Relevance and Insights on 1,4-Naphthoquinones as Antimicrobial and Antitumoral Molecules: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Quinones as Promising Compounds against Respiratory Viruses: A Review.Molecules (Basel, Switzerland) · 2023Review
- Review
- Advances in research on 3C-like protease (3CLRSC medicinal chemistry · 2023Review
- Evaluation of 1,4-naphthoquinone derivatives as antibacterial agents: activity and mechanistic studies.Frontiers of environmental science & engineering · 2023Article
- New Chemicals Suppressing SARS-CoV-2 Replication in Cell Culture.Molecules (Basel, Switzerland) · 2022Article
- The SARS-CoV-2 main protease (MMedComm · 2022Review
- Bioactive natural products in COVID-19 therapy.Frontiers in pharmacology · 2022Review
- A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 as a positive-sense single-stranded RNA coronavirus caused the global outbreak of COVID-19. The main protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.